TABLE 2.
5‐year overall survival (%) within strata.
| pN0/ENE‐negative | pN1‐2/ENE‐negative | pN1‐2/ENE‐positive | p‐value | |
|---|---|---|---|---|
| Overall | 62.8 | 56.7 | 32.9 | <.001 |
| Age at diagnosis, years | ||||
| 18–55 | 74.1 | 60.1 | 35.0 | <.001 |
| 56–69 | 63.8 | 57.7 | 35.1 | <.001 |
| 70 | 47.0 | 45.5 | 23.5 | <.001 |
| Sex | ||||
| Male | 61.0 | 55.3 | 31.8 | <.001 |
| Female | 69.2 | 61.1 | 36.0 | <.001 |
| Race | ||||
| White | 62.5 | 57.1 | 33.3 | <.001 |
| Black | 62.3 | 55.2 | 32.7 | <.001 |
| Other | 68.3 | 40.0 | 25.9 | .001 |
| Subsite | ||||
| Glottis | 63.2 | 56.9 | 24.3 | <.001 |
| Supraglottis | 62.8 | 56.9 | 35.4 | <.001 |
| Subglottis | 60.2 | 51.0 | 29.0 | .025 |
| Grade | ||||
| Well‐differentiated | 69.3 | 63.4 | 46.2 | .229 |
| Moderately differentiated | 64.3 | 55.3 | 29.7 | <.001 |
| Poorly differentiated, undifferentiated, anaplastic | 55.6 | 58.8 | 36.7 | <.001 |
| Pathologic AJCC group stage | ||||
| I | 78.4 | 93.5 | ‐ | .317 |
| II | 72.5 | 80.8 | 50.0 | .514 |
| III | 59.3 | 66.4 | 43.3 | .040 |
| IV | 58.4 | 51.5 | 32.3 | <.001 |
| pT classification | ||||
| 1 | 77.6 | 75.4 | 38.5 | <.001 |
| 2 | 68.9 | 67.0 | 46.7 | <.001 |
| 3 | 56.8 | 60.0 | 41.1 | <.001 |
| 4 | 60.2 | 49.5 | 24.1 | <.001 |
| pN classification | ||||
| 0 | 62.8 | ‐ | ‐ | ‐ |
| 1 | ‐ | 60.5 | 40.1 | <.001 |
| 2 | ‐ | 54.5 | 30.6 | <.001 |
| Adjuvant therapy | ||||
| None | 63.7 | 61.0 | 24.1 | <.001 |
| Radiotherapy alone | 61.9 | 55.8 | 30.7 | <.001 |
| Chemoradiotherapy | 60.7 | 53.7 | 36.7 | <.001 |
Note: Bold values are significant at p < 0.05.
Abbreviations: AJCC, American Joint Committee on Cancer; ENE, extranodal extension; pTN, pathologic tumor‐nodal.